Trial Profile
Bryostatin-1 Effect on HIV-1 Latency and Reservoir HIV-1 Infected Patients Receiving Antiretroviral Treatment: Pilot, Controlled, Double Blinded, Dose Searching Trial
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bryostatin (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms BRYOLAT
- 25 Feb 2016 Primary endpoint of intracellular HIV-1 RNA (usRNA and msRNA) level before and after bryostatin-1 administration has not been met, according to results presented at the 23rd Conference on Retroviruses and Opportunistic Infections.
- 25 Feb 2016 Results presented at the 23rd Conference on Retroviruses and Opportunistic Infections
- 17 Feb 2016 Results published in the AIDS